SCS vs Conventional Management for Chronic Pain
(SOLIS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
To evaluate the safety and effectiveness of Spinal Cord Stimulation (SCS) with multiple modalities compared to Conventional Medical Management (CMM) in patients with chronic low back and/or leg pain who have not undergone spinal surgery when using the Boston Scientific WaveWriter SCS Systems.
Who Is on the Research Team?
Natalie Bloom Lyons
Principal Investigator
Boston Scientific Corporation
Are You a Good Fit for This Trial?
This trial is for adults with chronic low back and/or leg pain lasting at least 6 months, who have tried other pain management treatments like medication or physical therapy for over 90 days. Women of childbearing age must not be pregnant. Participants must understand English to give informed consent. Those with vascular-origin pain, cervical lead implant needs, significant cognitive issues, or previous SCS trials are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Spinal Cord Stimulation or Conventional Medical Management
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Conventional Medical Management
- WaveWriter
Find a Clinic Near You
Who Is Running the Clinical Trial?
Boston Scientific Corporation
Lead Sponsor
Michael F. Mahoney
Boston Scientific Corporation
Chief Executive Officer since 2016
MBA from Wake Forest University, BBA in Finance from the University of Iowa
Kenneth Stein
Boston Scientific Corporation
Chief Medical Officer since 2020
MD from Harvard Medical School, MMSc in Clinical Investigation from Harvard-MIT Division of Health Sciences and Technology